Evidence map›Paper›PMID 18684827›Full record

ArticleJournal of virology2008

Herpes simplex virus type 2-induced mortality following genital infection is blocked by anti-tumor necrosis factor alpha antibody in CXCL10-deficient mice.

Manoj Thapa, Daniel J J Carr

Abstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Manoj ThapaDepartment of Ophthalmology, DMEI #415, University of Oklahoma Health Sciences Center, 608 Stanton L Young Blvd., Oklahoma City, OK 73104, USA.
Daniel J J Carr
Bipar · FRUniversity of Oklahoma Health Sciences Center · US

Funding

CORE--MOLECULAR BIOLOGYP30EY012190 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ANDERSON, ROBERT E · 1999 to 2009
$5.2M
The Role of CXCL9 in Genital HSV-2 InfectionR01AI067309 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CARR, DANIEL J · 2007 to 2009
$841k
NEI NIH HHS EY12190NEI NIH HHS P30 EY012190NIAID NIH HHS AI067309NIAID NIH HHS R01 AI067309
6 · The paper itself

Abstract

The role of tumor necrosis factor alpha (TNF-alpha) was evaluated for CXCL10-deficient (CXCL10(-/-)) mice which succumbed to genital herpes simplex virus type 2 (HSV-2) infection and possessed elevated levels of virus and TNF-alpha but not other cytokines in the central nervous system (CNS) and vaginal tissue within the first 7 days following virus exposure. Anti-TNF-alpha but not control antibody treatment offsets the elevated mortality rate of CXCL10(-/-) mice, despite increased CNS viral titers. In addition, TNF-alpha neutralization suppressed recruitment of leukocyte subpopulations into the CNS, which is associated with reduced CCL2 and CXCL9 expression. Collectively, the results implicate TNF-alpha as the principal mediator of mortality in response to genital HSV-2 infection.

Indexed as

Chemokine CXCL10Herpes GenitalisHerpesvirus 2, HumanAnimalsAntibodiesAntineoplastic Agents, HormonalBrain StemCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChemokine CXCL9FemaleMedroxyprogesterone AcetateMiceMice, KnockoutSpinal CordTumor Necrosis Factor-alphaAntibodiesAntineoplastic Agents, HormonalChemokine CXCL10Chemokine CXCL9Cxcl9 protein, mouseMedroxyprogesterone AcetateTumor Necrosis Factor-alpha

Identifiers

PMID18684827
PMCPMC2566256
OpenAlexW2160064875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.